Lepers by zzzmarcus


									From Wikipedia, the free encyclopedia


henson (Hansen’s Disease) Classification and external resources

A 24-year-old man infected with leprosy.

ICD-10 ICD-9 OMIM DiseasesDB MedlinePlus eMedicine MeSH

A30. 030 246300 8478 001347 med/1281 derm/223 neuro/187 C01.252.410.040.552.386

Leprosy (from the Greek lepi, meaning scales on a fish), or Hansen’s disease (HD), is a chronic disease caused by the bacteria Mycobacterium leprae and Mycobacterium lepromatosis.[1][2] Leprosy is primarily a granulomatous disease of the peripheral nerves and mucosa of the upper respiratory tract; skin lesions are the primary external symptom.[3] Left untreated, leprosy can be progressive, causing permanent damage to the skin, nerves, limbs and eyes. Contrary to popular belief, leprosy does not actually cause body parts to simply fall off.[4]

Historically, leprosy has affected mankind since at least 600 BC, and was well-recognized in the civilizations of ancient China, Egypt and India.[5] In 1995, the World Health Organization (WHO) estimated that between 2 and 3 million people were permanently disabled because of leprosy.[6] In the past 20 years, 15 million people worldwide have been cured of leprosy.[7] Although the forced quarantine or segregation of patients is unnecessary—and can be considered unethical—a few leper colonies still remain around the world, in countries such as India (there are still more than 1,000 leper colonies in India),[7] China,[8] Japan (until recently),[9] Romania,[10] Egypt, Nepal, Somalia, and Vietnam.[11] It is now commonly believed that many of the people who were segregated into these communities were presumed to have leprosy, when they actually had syphilis. Leprosy is not highly infectious, as approximately 95% of people are immune[12] and sufferers are no longer infectious after only a couple of days on treatment.[13][14] They would not have spread leprosy through a community, whereas syphilis, which has similar symptoms, is more contagious. The age-old social stigma associated with the advanced form of leprosy lingers in many areas, and remains a major obstacle to selfreporting and early treatment. Effective treatment for leprosy appeared in the late 1930s with the introduction of dapsone and its derivatives. However, leprosy bacilli resistant to dapsone gradually evolved and became widespread, and it was not until the introduction of multidrug therapy (MDT) in the early 1980s that the disease could be diagnosed and treated successfully within the community. MDT consists of Rifampicin, Dapsone, and Clofazimine, dosage adjusted appropriately for child and adult which is available in all PHCs in the form of blister packages. International Leprosy Day was created to draw awareness to Leprosy and its sufferers.


From Wikipedia, the free encyclopedia

agent in diffuse lepromatous leprosy, which can be lethal.[2][3] An intracellular, acid-fast bacterium, M. leprae is aerobic and rod-shaped, and is surrounded by the waxy cell membrane coating characteristic of Mycobacterium species.[21] Due to extensive loss of genes necessary for independent growth, M. leprae and M. lepromatosis are unculturable in the laboratory, a factor which leads to difficulty in definitively identifying the organism under a strict interpretation of Koch’s postulates.[2][22] The use of non-culture-based techniques such as molecular genetics has allowed for alternative establishment of causation.

There are several different approaches for classifying leprosy, but parallels exist. • The World Health Organization system distinguishes "paucibacillary" and "multibacillary" based upon the proliferation of bacteria[15] ("pauci-" refers to a low quantity.) • The Ridley-Jopling scale provides five gradations.[16][17] • The ICD-10, though developed by the WHO, uses Ridley-Jopling and not the WHO system. It also adds a indeterminate ("I") entry. • In MeSH, three groupings are used. There is a difference in immune response to the tuberculoid and lepromatous forms.[18][19] Hansen’s disease may also be divided into the following types:[20]:344-346 • Early and indeterminate leprosy • Tuberculoid leprosy • Borderline tuberculoid leprosy • Borderline leprosy • Borderline lepromatous leprosy • Lepromatous leprosy • Histoid leprosy


Several genes have been associated with a susceptibility to leprosy: Leprosy sufferers from leprosy home Bagamojo in German East Africa. The exact mechanism of transmission of leprosy is unknown: prolonged close contact and transmission by nasal droplet have both been proposed, and, while the latter fits the pattern of disease, both remain unproven.[23] The only other animals besides humans known to contract leprosy is the armadillo. [24] The bacterium can also be grown in the laboratory by injection into the footpads of mice.[25] There is evidence that not all people who are infected with M. leprae develop leprosy, and genetic factors have long been thought to play a role, due to the observation of clustering of leprosy around certain families, and the failure to understand why certain individuals develop lepromatous leprosy while others develop other types of leprosy.[26] It is estimated that due to genetic factors, only 5 percent of the population is susceptible to leprosy.[27] This is mostly because the body is naturally immune to the


Mycobacterium leprae, one of the causative agents of leprosy. As acid-fast bacteria, M. leprae appear red when a Ziehl-Neelsen stain is used. Mycobacterium leprae and Mycobacterium lepromatosis are the causative agents of leprosy. M. lepromatosis is only the causative


From Wikipedia, the free encyclopedia
WHO RidleyJopling ICD-10 MeSH Tuberculoid Description

Lepromin Immune test target bacillus (Th1)

Paucibacillary tuberculoid A30.1, ("TT"), borA30.2 derline tuberculoid ("BT")

It is characterized Positive by one or more hypopigmented skin macules and anaesthetic patches, where skin sensations are lost because of damaged peripheral nerves that have been attacked by the human host’s immune cells. Borderline leprosy is of intermediate severity and is the most common form. Skin lesions resemble tuberculoid leprosy but are more numerous and irregular; large patches may affect a whole limb, and peripheral nerve involvement with weakness and loss of sensation is common. This type is unstable and may become more like lepromatous leprosy or may undergo a reversal reaction, becoming more like the tuberculoid form.

Multibacillary midborderline A30.3 or borderline ("BB")


Multibacillary borderline lepromatous ("BL"), and lepromatous ("LL")

A30.4, A30.5

Lepromatous It is associated Negative with symmetric skin lesions, nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and epistaxis (nose bleeds) but typically detectable

plasmid inside bacillus (Th2)


From Wikipedia, the free encyclopedia
nerve damage is late. Name LPRS1 LPRS2 LPRS3 LPRS4 Locus 10p13 6q25 4q32 6p21.3 OMIM 609888 607572 246300 610988 PARK2, PACRG TLR2 LTA Gene


bacteria, and those persons who do become infected are experiencing a severe allergic reaction to the disease. However, the role of genetic factors is not entirely clear in determining this clinical expression. In addition, malnutrition and prolonged exposure to infected persons may play a role in development of the overt disease. The incubation period for the bacteria can last anywhere from two to ten years. The most widely held belief is that the disease is transmitted by contact between infected persons and healthy persons.[28] In general, closeness of contact is related to the dose of infection, which in turn is related to the occurrence of disease. Of the various situations that promote close contact, contact within the household is the only one that is easily identified, although the actual incidence among contacts and the relative risk for them appear to vary considerably in different studies. In incidence studies, infection rates for contacts of lepromatous leprosy have varied from 6.2 per 1000 per year in Cebu, Philippines[29] to 55.8 per 1000 per year in a part of Southern India.[30] Two exit routes of M. leprae from the human body often described are the skin and the nasal mucosa, although their relative importance is not clear. It is true that lepromatous cases show large numbers of organisms deep down in the dermis. However, whether they reach the skin surface in sufficient numbers is doubtful. Although there are reports of acid-fast bacilli being found in the desquamating epithelium (sloughing of superficial layer of skin) of the skin, Weddell et al. had reported in 1963 that they could not find any acid-fast bacilli in the epidermis, even after examining a very large number of specimens from patients and contacts.[31] In a recent study, Job et al. found fairly large numbers of M. leprae in the superficial keratin layer of the skin of lepromatous leprosy

patients, suggesting that the organism could exit along with the sebaceous secretions.[32] The importance of the nasal mucosa was recognized as early as 1898 by Schäffer, particularly that of the ulcerated mucosa.[33] The quantity of bacilli from nasal mucosal lesions in lepromatous leprosy was demonstrated by Shepard as large, with counts ranging from 10,000 to 10,000,000.[34] Pedley reported that the majority of lepromatous patients showed leprosy bacilli in their nasal secretions as collected through blowing the nose.[35] Davey and Rees indicated that nasal secretions from lepromatous patients could yield as much as 10 million viable organisms per day.[36] The entry route of M. leprae into the human body is also not definitely known. The two seriously considered are the skin and the upper respiratory tract. While older research dealt with the skin route, recent research has increasingly favored the respiratory route. Rees and McDougall succeeded in the experimental transmission of leprosy through aerosols containing M. leprae in immune-suppressed mice, suggesting a similar possibility in humans.[37] Successful results have also been reported on experiments with nude mice when M. leprae were introduced into the nasal cavity by topical application.[38] In summary, entry through the respiratory route appears the most probable route, although other routes, particularly broken skin, cannot be ruled out. The CDC notes the following assertion about the transmission of the disease: "Although the mode of transmission of Hansen’s disease remains uncertain, most investigators think that M. leprae is usually spread from person to person in respiratory droplets."[39] In leprosy both the reference points for measuring the incubation period and the times of infection and onset of disease are difficult to define; the former because of the lack of adequate immunological tools and the


From Wikipedia, the free encyclopedia
latter because of the disease’s slow onset. Even so, several investigators have attempted to measure the incubation period for leprosy. The minimum incubation period reported is as short as a few weeks and this is based on the very occasional occurrence of leprosy among young infants.[40] The maximum incubation period reported is as long as 30 years, or over, as observed among war veterans known to have been exposed for short periods in endemic areas but otherwise living in non-endemic areas. It is generally agreed that the average incubation period is between 3 and 5 years.

endemic countries. In 1985 leprosy was still considered a public-health problem in 122 countries. The 44th World Health Assembly (WHA), held in Geneva in 1991, passed a resolution to eliminate leprosy as a public-health problem by the year 2000—defined as reducing the global prevalence of the disease to less than 1 case per 100,000. At the Assembly, the World Health Organization (WHO) was given the mandate to develop an elimination strategy by its member states, based on increasing the geographical coverage of MDT and patients’ accessibility to the treatment. The WHO Study Group’s report on the Chemotherapy of Leprosy in 1993 recommended two types of standard MDT regimen be adopted.[43] The first was a 24-month treatment for multibacillary (MB or lepromatous) cases using rifampicin, clofazimine, and dapsone. The second was a six-month treatment for paucibacillary (PB or tuberculoid) cases, using rifampicin and dapsone. At the First International Conference on the Elimination of Leprosy as a Public Health Problem, held in Hanoi the next year, the global strategy was endorsed and funds provided to WHO for the procurement and supply of MDT to all endemic countries.


MDT patient packs and blisters Until the development of dapsone in the 1940s, there was no effective treatment for leprosy. However, dapsone is only weakly bactericidal against M. leprae and it was considered necessary for patients to take the drug indefinitely. Moreover, when dapsone was used alone, the M. leprae population quickly evolved antibiotic resistance; by the 1960s, the world’s only known anti-leprosy drug became virtually useless. The search for more effective anti-leprosy drugs than dapsone led to the use of clofazimine and rifampicin in the 1960s and 1970s.[41] Later, Indian scientist Shantaram Yawalkar and his colleagues formulated a combined therapy using rifampicin and dapsone, intended to mitigate bacterial resistance.[42] Multidrug therapy (MDT) and combining all three drugs was first recommended by a WHO Expert Committee in 1981. These three anti-leprosy drugs are still used in the standard MDT regimens. None of them are used alone because of the risk of developing resistance. Because this treatment was quite expensive, it was not quickly adopted in most

MDT anti-leprosy drugs: standard regimens Between 1995 and 1999, WHO, with the aid of the Nippon Foundation (Chairman Yōhei Sasakawa, World Health Organization Goodwill Ambassador for Leprosy Elimination), supplied all endemic countries with free MDT in blister packs, channelled through Ministries of Health. This free provision was extended in 2000 with a donation by the MDT manufacturer Novartis, which will run until at least the end of 2010. At the national level, non-government organizations (NGOs) affiliated to the national programme will continue to be provided with an


From Wikipedia, the free encyclopedia
appropriate free supply of this WHO supplied MDT by the government. MDT remains highly effective, and patients are no longer infectious after the first monthly dose.[5] It is safe and easy to use under field conditions due to its presentation in calendar blister packs.[5] Relapse rates remain low, and there is no known resistance to the combined drugs.[5] The Seventh WHO Expert Committee on Leprosy,[44] reporting in 1997, concluded that the MB duration of treatment—then standing at 24 months—could safely be shortened to 12 months "without significantly compromising its efficacy." Persistent obstacles to the elimination of the disease include improving detection, educating patients and the population about its cause, and fighting social taboos about a disease whose patients have historically been considered "unclean" or "cursed by God" as outcasts. Where taboos are strong, patients may be forced to hide their condition (and avoid seeking treatment) to avoid discrimination. The lack of awareness about Hansen’s disease can lead people to falsely believe that the disease is highly contagious and incurable. The ALERT hospital and research facility in Ethiopia provides training to medical personnel from around the world in the treatment of leprosy, as well as treating many local patients. Surgical techniques, such as for the restoration of control of movement of thumbs, have been developed there.


World distribution of leprosy, 2003. number of cases, with Brazil second and Burma third. In 1999, the world incidence of Hansen’s disease was estimated to be 640,000. In 2000, 738,284 cases were identified.[49] In 1999, 108 cases occurred in the United States. In 2000, the World Health Organization (WHO) listed 91 countries in which Hansen’s disease is endemic. India, Myanmar and Nepal contained 70% of cases. India reports over 50% of the world’s leprosy cases.[50] In 2002, 763,917 new cases were detected worldwide, and in that year the WHO listed Brazil, Madagascar, Mozambique, Tanzania and Nepal as having 90% of Hansen’s disease cases. According to recent figures from the WHO, new cases detected worldwide have decreased by approximately 107,000 cases (or 21%) from 2003 to 2004. This decreasing trend has been consistent for the past three years. In addition, the global registered prevalence of HD was 286,063 cases; 407,791 new cases were detected during 2004. In the United States, Hansen’s disease is tracked by the Centers for Disease Control and Prevention (CDC), with a total of 92 cases being reported in 2002.[51] Although the number of cases worldwide continues to fall, pockets of high prevalence continue in certain areas such as Brazil, South Asia (India, Nepal), some parts of Africa (Tanzania, Madagascar, Mozambique) and the western Pacific.

In a recent trial, a single dose of rifampicin reduced the rate at which contacts acquired leprosy in the two years after contact by 57%; 265 treatments with rifampicin prevented one case of leprosy in this period.[45] A non-randomized study found that rifampicin reduced the number of new cases of leprosy by 75% after three years.[46] BCG offers a variable amount of protection against leprosy as well as against tuberculosis.[47][48]

Risk groups
At highest risk are those living in endemic areas with poor conditions such as inadequate bedding, contaminated water and insufficient diet, or other diseases (such as HIV) that compromise immune function. Recent research suggests that there is a defect in cell-mediated immunity that causes susceptibility to the disease. Less than ten

Worldwide, two to three million people are estimated to be permanently disabled because of Leprosy.[6] India has the greatest


From Wikipedia, the free encyclopedia
percent of the world’s population is actually capable of acquiring the disease. The region of DNA responsible for this variability is also involved in Parkinson disease, giving rise to current speculation that the two disorders may be linked in some way at the biochemical level. In addition, men are twice as likely to contract leprosy as women. According to The Leprosy Mission Canada, most people – about 95% of the population – are naturally immune. Region


Registered New case detection duri prevalence (rate/ 1,000,000 pop.) Start of 2006 2001 39,612 42,830 2002 48,248 39,939 2003 47,006 52,435

Africa Americas South-East Asia

40,830 (0.56) 32,904 (0.39) 133,422 (0.81)

Disease burden
Although annual incidence—the number of new leprosy cases occurring each year—is important as a measure of transmission, it is difficult to measure in leprosy due to its long incubation period, delays in diagnosis after onset of the disease and the lack of laboratory tools to detect leprosy in its very early stages. - - Instead, the registered prevalence is used. Registered prevalence is a useful proxy indicator of the disease burden as it reflects the number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time. The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.[52] New case detection is another indicator of the disease that is usually reported by countries on an annual basis. It includes cases diagnosed with onset of disease in the year in question (true incidence) and a large proportion of cases with onset in previous years (termed a backlog prevalence of undetected cases). The new case detection rate (NCDR) is defined by the number of newly detected cases, previously untreated, during a year divided by the population in which the cases have occurred. Endemic countries also report the number of new cases with established disabilities at the time of detection, as an indicator of the backlog prevalence. However, determination of the time of onset of the disease is generally unreliable, is very labor-intensive and is seldom done in recording these statistics.

668,658 520,632 405,147 4,758 7,404 4,665 7,154 3,940 6,190

Eastern 4,024 Mediterranean (0.09) Western Pacific Totals 8,646 (0.05) 219,826

763,262 620,638 514,718

Table 2: Prevalence and detection, countries still to rea elimination Countries Registered prevalence (rate/10,000 pop.) Start of 2004 Brazil Start of 2005 Start of 2006

New case detec (rate/100,000 p

During During 2003 2004 49,384 (26.9) 4,266 (22.0) 6,958 (26.2) 5,190 (13.8) NA

79,908 30,693 27,313 49,206 (4.6) (1.7) (1.5) (28.6) 4,692 (2.4) 4,699 (1.8) 4,777 (1.3) NA 4,889 (2.5) 4,921 (1.8) 4,190 (1.1) NA 5,907 (29.4) 8,046 (32.9) 5,279 (15.4) NA

6,810 Mozambique (3.4) Nepal 7,549 (3.1)

Tanzania 5,420 (1.6) Totals NA

As reported to WHO by 115 countries and territories in 2006, and published in the Weekly Epidemiological Record the global registered prevalence of leprosy at the beginning of the year was 219,826 cases.[53] New case detection during the previous year (2005 - the last year for which full country information is available) was 296,499. The reason for the annual detection being higher than the prevalence at the end of the year can be explained by the fact that a proportion Global situation of new cases complete their treatment within Table 1: Prevalence at beginning of 2006, and trends in new case detectionlonger remain on the year and therefore no 2001-2005, excluding Europe the registers. The global detection of new cases continues to show a sharp decline,


From Wikipedia, the free encyclopedia
falling by 110,000 cases (27%) during 2005 compared with the previous year. Table 1 shows that global annual detection has been declining since 2001. The African region reported an 8.7% decline in the number of new cases compared with 2004. The comparable figure for the Americas was 20.1%, for South-East Asia 32% and for the Eastern Mediterranean it was 7.6%. The Western Pacific area, however, showed a 14.8% increase during the same period. Table 2 shows the leprosy situation in the four major countries which have yet to achieve the goal of elimination at the national level. It should be noted that: a) Elimination is defined as a prevalence of less than 1 case per 10,000 population; b) Madagascar reached elimination at the national level in September 2006; c) Nepal detection reported from mid-November 2004 to mid-November 2005; and d) D.R. Congo officially reported to WHO in 2008 that it had reached elimination by the end of 2007, at the national level.


In regards to ancient China, Katrina C. D. McLeod and Robin D. S. Yates identify the State of Qin’s Feng zhen shi ??? (Models for sealing and investigating), dated 266-246 BC, as offering the earliest known unambiguous description of the symptoms of low-resistance leprosy, even though it was termed then under li ?, a general Chinese word for skin disorder.[60] This 3rd century BC Chinese text on bamboo slip, found in an excavation of 1975 at Shuihudi, Yunmeng, Hubei province, not only described the destruction of the "pillar of the nose", but also the "swelling of the eyebrows, loss of hair, absorption of nasal cartilage, affliction of knees and elbows, difficult and hoarse respiration, as well as anesthesia."[60]

In the West, the earliest known description of leprosy there was made by the Roman encyclopedist Aulus Cornelius Celsus (25 BC – 37 AD) in his De Medicina; he called leprosy "elephantiasis".[60] The Roman author Pliny the Elder (23–79 AD) mentioned the same disease.[60] Although "sara’t" of Leviticus (Old Testament) is translated as "lepra" in the 5th century AD Vulgate, the original term sara’t found in Leviticus was not the elephantiasis described by Celsus and Pliny; in fact, sara’t was used to describe a disease which could affect houses and clothing.[60] Katrina C. D. McLeod and Robin D. S. Yates state that sara’t "denotes a condition of ritual impurity or a temporary form of skin disease."[60]

The Oxford Illustrated Companion to Medicine holds that the mention of leprosy, as well as ritualistic cures for it, were already described in the Hindu religious book Atharva-veda.[54] Writing in the Encyclopedia Britannica 2008, Kearns & Nash state that the first mention of leprosy is described in the Indian medical treatise Sushruta Samhita (6th century BC).[55] The Cambridge Encyclopedia of Human Paleopathology (1998) holds that: "The Sushruta Samhita from India describes the condition quite well and even offers therapeutic suggestions as early as about 600 BC"[56] The surgeon Sushruta flourished in the Indian city of Kashi by the 6th century BC,[57] and the medical treatise Sushruta Samhita—attributed to him—made its appearance during the 1st millennium BC.[55] The earliest surviving excavated written material which contains the works of Sushruta is the Bower Manuscript—dated to the 4th century AD, almost a millennium after the original work.[58] In 1881, around 120,000 leprosy patients existed in India. The central government passed the Lepers Act of 1898, which provided legal provision for forcible confinement of leprosy sufferers in India.[59]

Muslim world
In the Muslim world, the Persian polymath Avicenna (c. 980–1037) was the first outside of China to describe the destruction of the nasal septum in those suffering from leprosy.[60]

Middle ages
Numerous leprosaria, or leper hospitals, sprang up in the Middle Ages; Matthew Paris estimated that in the early thirteenth century there were 19,000 across Europe.[61] The first recorded Leper colony was in Harbledown. These institutions were run along monastic lines and, while lepers were encouraged to live in these monastic-type establishments,


From Wikipedia, the free encyclopedia
this was for their own health as well as quarantine. Indeed, some medieval sources indicate belief that those suffering from leprosy were considered to be going through Purgatory on Earth, and for this reason their suffering was considered holier than the ordinary person’s. More frequently, lepers were seen to exist in a place between life and death: they were still alive, yet many chose or were forced to ritually separate themselves from mundane existence.[62] The Order of Saint Lazarus was a hospitaller and military order of monks that began as a leper hospital outside Jerusalem in the twelfth century and remained associated with leprosy throughout its history. The first monks in this order were leper knights and they originally had leper grand masters, although these aspects of the order changed over the centuries. Radegund was noted for washing the feet of lepers. Orderic Vitalis writes of a monk, Ralf, who was so overcome by the plight of lepers that he prayed to catch leprosy himself (which he eventually did). The leper would carry a clapper and bell to warn of his approach, and this was as much to attract attention for charity as to warn people that a diseased person was near.


G. H. A. Hansen, discoverer of M. leprae Historically, individuals with Hansen’s disease have been known as lepers; however, this term is falling into disuse as a result of the diminishing number of leprosy patients and the pejorative connotations of the term. The term most widely accepted among professionals is "people affected by Hansen’s disease." Historically, the term Tzaraath from the Hebrew Bible was, erroneously, commonly translated as leprosy, although the symptoms of Tzaraath were not entirely consistent with leprosy and rather referred to a variety of disorders other than Hansen’s disease.[67] In particular, tinea capitis (fungal scalp infection) and related infections on other body parts caused by the dermatophyte fungus Trichophyton violaceum are abundant throughout the Middle East and North Africa today and might also have been common in biblical times. Similarly, the related agent of the disfiguring skin disease favus, Trichophyton schoenleinii, appears to have been common throughout Eurasia and Africa before the advent of modern medicine. Persons with severe favus and similar fungal diseases (and potentially also with severe psoriasis

Mycobacterium leprae, the causative agent of leprosy, was discovered by G. H. Armauer Hansen in Norway in 1873, making it the first bacterium to be identified as causing disease in humans.[63][64] He worked at St. Jørgens Hospital in Bergen, founded early in the fifteenth century. St. Jørgens is today a museum, Lepramuseet, probably the best preserved leprosy hospital in Northern Europe.[65]

The word "leprosy" derives from the ancient Greek words lepros, a scale, and lepein, to peel.[66] The word came into the English language via Latin and Old French. The first attested English use is in the Ancrene Wisse, a 13th-century manual for nuns ("Moyseses hond..bisemde o þe spitel uuel & þuhte lepruse." The Middle English Dictionary, s.v., "leprous"). A roughly contemporaneous use is attested in the Anglo-Norman Dialogues of Saint Gregory, "Esmondez i sont li lieprous" (Anglo-Norman Dictionary, s.v., "leprus").


From Wikipedia, the free encyclopedia
and other diseases not caused by microorganisms) tended to be classed as having leprosy as late as the 17th century in Europe.[68] This is clearly shown in the painting The Regents of the Leper Hospital in Haarlem 1667 by Jan de Bray (Frans Hals Museum, Haarlem, the Netherlands), where a young Dutchman with a vivid scalp infection, almost certainly caused by a fungus, is shown being cared for by three officials of a charitable home intended for leprosy sufferers. The use of the word "leprosy" before the mid-19th century, when microscopic examination of skin for medical diagnosis was first developed, can seldom be correlated reliably with Hansen’s disease as we understand it today.

11791665. http://www.jstage.jst.go.jp/ article/mandi/45/11/729/_pdf. [2] ^ http://www.sciencedaily.com/releases/ 2008/11/081124141047.htm [3] ^ Kenneth J. Ryan, C. George Ray, editors. (2004). Ryan KJ, Ray CG. ed. Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 451–3. ISBN 0838585299. OCLC 52358530 61405904. [4] "Lifting the stigma of leprosy: a new vaccine offers hope against an ancient disease". Time 119 (19): 87. May 1982. PMID 10255067. http://www.time.com/ time/magazine/article/ 0,9171,925377,00.html. [5] ^ "Leprosy". WHO. http://www.who.int/ mediacentre/factsheets/fs101/en/. Retrieved on 2007-08-22. [6] ^ WHO (1995). "Leprosy disabilities: magnitude of the problem". Weekly Epidemiological Record 70 (38): 269–75. PMID 7577430. [7] ^ The hidden suffering of India’s lepers. BBC News. March 31, 2007. [8] ’Ignorance breeds leper colonies in China’. Independent News & Media. September 13, 2006. [9] Koizumi apologises for leper colonies. BBC News. May 25, 2001. [10] Europe’s last leper colony lives on. BBC News. November 6, 2001. [11] “Making Peace With Vietnam” to be screened at Beijing film festival. VOVNEWS.VN. 02/08/2009 [12] http://www.leprosy.org/getinformed/ aboutleprosy/leprosyfaq.php [13] http://www.leprosy.org/getinformed/ aboutleprosy/statistics.php [14] http://www.leprosy.org/getinformed/ aboutleprosy/basics.php [15] "Leprosy: Overview - eMedicine Infectious Diseases". http://emedicine.medscape.com/article/ 220455-overview. Retrieved on 2009-03-09. [16] Singh N, Manucha V, Bhattacharya SN, Arora VK, Bhatia A (June 2004). "Pitfalls in the cytological classification of borderline leprosy in the Ridley-Jopling scale". Diagn. Cytopathol. 30 (6): 386–8. doi:10.1002/dc.20012. PMID 15176024. [17] Ridley DS, Jopling WH (1966). "Classification of leprosy according to immunity. A five-group system". Int. J.

Famous lepers
• Blessed Damien of Moloka’i was a Roman Catholic missionary-priest who became a leper while serving the leper colony at Moloka’i. He continued to serve the lepers until he died from the effects of the disease himself. He will be canonized (declared a saint) on Oct. 11th, 2009 at a Vatican ceremony presided over by Pope Benedict XVI.[69] • King Baldwin IV of Jerusalem. • The Bible mentions many people who were afflicted with leprosy: Moses’ sister Miriam (Numbers 12:9-16), Moses himself (Exodus 4:6, 7), Syrian army chief Naaman and later the prophet Elisha’s servant Gehazi (2 Kings 5:1-27). Healing people of leprosy is listed among the miracles of Jesus Christ (Luke 5:12-16, 17:11-19). • Robert Vincent Giglio III • Possibly Robert the Bruce, King of Scots. • Vietnamese poet Han Mac Tu • Otani Yoshitsugu, a Japanese Daimyo. • In fiction, the protagonist of The Chronicles of Thomas Covenant contracts leprosy, the central point of the entire series. Hamlet’s father suffers from leprosy as well.

[1] Sasaki S, Takeshita F, Okuda K, Ishii N (2001). "Mycobacterium leprae and leprosy: a compendium". Microbiol Immunol 45 (11): 729–36. PMID


From Wikipedia, the free encyclopedia


[28] Kaur H, Van Brakel W (2002). Lepr. Other Mycobact. Dis. 34 (3): "Dehabilitation of leprosy-affected 255–73. PMID 5950347. people—a study on leprosy-affected [18] Modlin RL (June 1994). "Th1-Th2 paradigm: insights from leprosy". J. beggars". Leprosy review 73 (4): 346–55. PMID 12549842. Invest. Dermatol. 102 (6): 828–32. PMID [29] Doull JA, Guinto RA, Rodriguez RS, et al. 8006444. (1942). "The incidence of leprosy in [19] "The disease leprosy is caused by Cordova and Talisay, Cebu, Philippines". infection with Mycobacterium leprae". http://www1.indstate.edu/thcme/PSP/ International Journal of Leprosy 10: 04psp/TH1VTH204.htm. Retrieved on 107–131. 2009-03-03. [30] Noordeen S, Neelan P (1978). "Extended [20] James, William D.; Berger, Timothy G.; et studies on chemoprophylaxis against al. (2006). Andrews’ Diseases of the leprosy". Indian J Med Res 67: 515–27. Skin: clinical Dermatology. Saunders PMID 355134. Elsevier. ISBN 0-7216-2921-0. [31] Weddell G, Palmer E (1963). "The [21] McMurray DN (1996). Mycobacteria and pathogenesis of leprosy. An experimental Nocardia. in: Baron’s Medical approach". Leprosy Review 34: 57–61. Microbiology (Baron S et al., eds.) (4th PMID 13999438. ed.). Univ of Texas Medical Branch. [32] Job C, Jayakumar J, Aschhoff M (1999). ISBN 0-9631172-1-1. OCLC 33838234. ""Large numbers" of Mycobacterium http://www.ncbi.nlm.nih.gov/books/ leprae are discharged from the intact bv.fcgi?rid=mmed.section.1833. skin of lepromatous patients; a [22] Bhattacharya S, Vijayalakshmi N, Parija preliminary report". Int J Lepr Other SC (01 Oct 2002). "Uncultivable Mycobact Dis 67 (2): 164–7. PMID bacteria: Implications and recent trends 10472371. towards identification". Indian journal of [33] Arch Dermato Syphilis 1898; 44:159–174 medical microbiology 20 (4): 174–7. [34] Shepard C (1960). "Acid-fast bacilli in PMID 17657065. http://www.ijmm.org/ nasal excretions in leprosy, and results article.asp?issn=0255-0857;year=2002;volume=20;issue=4;spage=174;epage=177;aulast=Bhattacha of inoculation of mice". Am J Hyg 71: [23] Reich CV (1987). "Leprosy: cause, 147–57. PMID 14445823. transmission, and a new theory of [35] Pedley J (1973). "The nasal mucus in pathogenesis". Rev. Infect. Dis. 9 (3): leprosy". Lepr Rev 44 (1): 33–5. PMID 590–4. PMID 3299638. 4584261. [24] Rojas-Espinosa O, Løvik M (2001). [36] Davey T, Rees R (1974). "The nasal "Mycobacterium leprae and dicharge in leprosy: clinical and Mycobacterium lepraemurium infections bacteriological aspects". Lepr Rev 45 in domestic and wild animals". Rev. - Off. (2): 121–34. PMID 4608620. Int. Epizoot. 20 (1): 219–51. PMID [37] Rees R, McDougall A (1977). "Airborne 11288514. infection with Mycobacterium leprae in [25] Hastings RC, Gillis TP, Krahenbuhl JL, mice". J Med Microbiol 10 (1): 63–8. Franzblau SG (01 Jul 1988). "Leprosy". PMID 320339. Clin. Microbiol. Rev. 1 (3): 330–48. PMID [38] Chehl S, Job C, Hastings R (1985). 3058299. "Transmission of leprosy in nude mice". http://www.pubmedcentral.nih.gov/ Am J Trop Med Hyg 34 (6): 1161–6. articlerender.fcgi?tool=pubmed&pubmedid=3058299. 3914846. PMID [26] Alcaïs A, Mira M, Casanova JL, Schurr E, [39] CDC Disease Info hansens_t Hansen’s Abel L (2005). "Genetic dissection of Disease (Leprosy) immunity in leprosy". Curr. Opin. [40] Montestruc E, Berdonneau R (1954). "2 Immunol. 17 (1): 44–8. doi:10.1016/ New cases of leprosy in infants in j.coi.2004.11.006. PMID 15653309. Martinique" (in French). Bull Soc Pathol [27] "AR Dept of Health debunks leprosy Exot Filiales 47 (6): 781–3. PMID fears". 2008-02-08. 14378912. http://www.kfsm.com/Global/ [41] Rees RJ, Pearson JM, Waters MF (1970). story.asp?S=7845322. Retrieved on "Experimental and clinical studies on 2008-04-08.


From Wikipedia, the free encyclopedia


rifampicin in treatment of leprosy". Br (Geneva: World Health Organization) Med J 688 (1): 89–92. PMID 4903972. 716: 1–60. 1985. ISBN 9241207167. [42] Yawalkar SJ, McDougall AC, Languillon J, OCLC 12095109. PMID 3925646. Ghosh S, Hajra SK, Opromolla DV, [53] "Global leprosy situation, 2006" (PDF). Tonello CJ (1982). "Once-monthly Weekly Epidemiological Record 81 (32): rifampicin plus daily dapsone in initial 309–16. August 2006. PMID 16903018. treatment of lepromatous leprosy". http://www.who.int/lep/resources/ Lancet 8283 (1): 1199–1202. wer8132.pdf. doi:10.1016/S0140-6736(82)92334-0. [54] Lock etc., page 420 PMID 6122970. [55] ^ Kearns & Nash (2008) [43] "Chemotherapy of Leprosy". WHO [56] Aufderheide, A. C.; Rodriguez-Martin, C. Technical Report Series 847. WHO. & Langsjoen, O. (1998). The Cambridge 1994. http://www.who.int/lep/mdt/ Encyclopedia of Human Paleopathology. chemotherapy/en/index.html. Retrieved Cambridge University Press. ISBN on 2007-03-24. 0521552036. Page 148. [44] "Seventh WHO Expert Committee on [57] Dwivedi & Dwivedi (2007) Leprosy". WHO Technical Report Series [58] Kutumbian, P. (2005). Ancient Indian 874. WHO. 1998. http://www.who.int/lep/ Medicine. Orient Longman. ISBN resources/expert/en/index.html. 8125015213. pages XXXII-XXXIII. Retrieved on 2007-03-24. [59] Leprosy - Medical History of British [45] Moet FJ, Pahan D, Oskam L, Richardus India, National Library of Scotland JH (2008). "Effectiveness of single dose [60] ^ McLeod, Katrina C. D. and Robin D. S. rifampicin in preventing leprosy in close Yates (June 1981). "Forms of Ch’in Law: contacts of patients with newly An Annotated Translation of The Fengdiagnosed leprosy: cluster randomised chen shih". Harvard Journal of Asiatic controlled trial". BMJ 336: 761. Studies 41 (1): 111–63. Pages 152–3 & doi:10.1136/bmj.39500.885752.BE. footnote 147. doi:10.2307/2719003. PMID 18332051. [61] "Leprosy". Catholic Encyclopedia. [46] Bakker MI, Hatta M, Kwenang A, et al. New York: Robert Appleton Company. (01 Apr 2005). "Prevention of leprosy 1913. http://en.wikisource.org/wiki/ using rifampicin as chemoprophylaxis". Catholic_Encyclopedia_(1913)/Leprosy. Am J Trop Med Hyg 72 (4): 443–8. PMID [62] Brody, Saul Nathaniel (1974). The 15827283. http://www.ajtmh.org/cgi/ Disease of the Soul: Leprosy in Medieval content/abstract/72/4/ Literature. Ithaca: Cornell Press. 443?ijkey=4b15a78b876fd990dfd877ee89b22399c026501c&keytype2=tf_ipsecsha. [63] Hansen GHA (1874). "Undersøgelser [47] Fine PE, Smith PG (1996). "Vaccination Angående Spedalskhedens Årsager against leprosy—the view from 1996". (Investigations concerning the etiology Lepr Rev 67 (4): 249–52. PMID of leprosy)" (in Norwegian). Norsk Mag. 9033195. Laegervidenskaben 4: 1–88. [48] Karonga prevention trial group (1996). [64] Irgens L (2002). "The discovery of the "Randomized controlled trial of single leprosy bacillus". Tidsskr nor Laegeforen BCG, repeated BCG, or combined BCG 122 (7): 708–9. PMID 11998735. and killed Mycobacterium leprae vaccine [65] Bymuseet i Bergen for prevention of leprosy and [66] Barnhart RK (1995). Barnhart Concise tuberculosis in Malawi". Lancet 348: Dictionary of Etymology. New York: 17–24. doi:10.1016/ Harper Collins. ISBN 0062700847. OCLC S0140-6736(96)02166-6. PMID 221898877 223496345 231655185 8691924. 30399281. [49] Last Days Of A Leper Colony. CBC News. [67] Artscroll Tanakh, Leviticus 13:59, 1996 March 22, 2003. [68] Kane J, Summerbell RC, Sigler L, [50] Surgery grants for leprosy sufferers in Krajden S, Land G (1997). Laboratory India. Times of India. February 2, 2009. Handbook of Dermatophytes: A clinical [51] CDC Leprosy Fact Sheet. guide and laboratory manual of [52] "Epidemiology of leprosy in relation to dermatophytes and other filamentous control. Report of a WHO Study Group". fungi from skin, hair and nails. Star World Health Organ Tech Rep Ser


From Wikipedia, the free encyclopedia
Publishers (Belmont, CA). ISBN 0898631572. OCLC 37116438. [69] Priest who aided lepers in Hawaii to become saint http://news.yahoo.com/s/ap/20090221/ ap_on_re_eu/eu_vatican_saint


External links
Leprosy at the Open Directory Project

Retrieved from "http://en.wikipedia.org/wiki/Leprosy" Categories: Leprosy, Bacterial skin conditions, Bacterial diseases, Tropical diseases, Neglected diseases This page was last modified on 24 May 2009, at 21:42 (UTC). All text is available under the terms of the GNU Free Documentation License. (See Copyrights for details.) Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a U.S. registered 501(c)(3) taxdeductible nonprofit charity. Privacy policy About Wikipedia Disclaimers


To top